ストックスクリーナーアプリを入手
29.77
3.44%
0.99
アフターアワーズ：
29.77
前日終値:
$28.78
開ける：
$28.88
24時間の取引高:
315.50K
Relative Volume:
1.79
時価総額：
$493.21M
収益：
$102.48M
当期純損益:
$-191.09M
株価収益率:
-2.0645
EPS:
-14.4203
ネットキャッシュフロー:
$-178.93M
1週間 パフォーマンス:
+10.06%
1か月 パフォーマンス:
+28.99%
6か月 パフォーマンス:
+281.67%
1年 パフォーマンス:
+413.72%
1日の値動き範囲:
$28.78
$30.50
1週間の範囲:
$24.94
$30.50
52週間の値動き範囲:
$5.231
$30.50
Sutro Biopharma Inc Stock (STRO) Company Profile
名前
Sutro Biopharma Inc
セクター
電話
650-392-8412
住所
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
29.77 | 476.81M | 102.48M | -191.09M | -178.93M | -14.42 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-07 | 開始されました | Leerink Partners | Outperform |
| 2026-03-24 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2026-03-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-01-20 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2025-03-14 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-05-08 | 開始されました | BofA Securities | Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Buy |
| 2023-10-06 | 開始されました | Oppenheimer | Outperform |
| 2023-03-21 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | 再開されました | Wells Fargo | Overweight |
| 2021-06-18 | 開始されました | H.C. Wainwright | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-09-02 | 開始されました | Jefferies | Buy |
| 2020-07-16 | 開始されました | Wells Fargo | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-10-07 | 開始されました | BTIG Research | Buy |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2019-04-29 | 開始されました | H.C. Wainwright | Buy |
| 2018-10-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-10-22 | 開始されました | Piper Jaffray | Overweight |
| 2018-10-22 | 開始されました | Wedbush | Outperform |
すべてを表示
Sutro Biopharma Inc (STRO) 最新ニュース
Sutro Biopharma Hits New 52-Week High - National Today
Momentum Shift: Is Sutro Biopharma Inc benefiting from interest rate changes2026 Drop Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Sutro Biopharma (STRO) price target decreased by 21.62% to 29.58 - MSN
Sutro Biopharma Receives 'Moderate Buy' Rating from Analysts - National Today
Sutro Biopharma, Inc. (STRO) stock price, news, quote and history - Yahoo Finance UK
Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last? - Yahoo Finance
Leerink Partners Initiates Sutro Biopharma at Outperform With $38 Price Target - Moomoo
Rate Cut: What is the Moat Score of Sutro Biopharma IncWeekly Trading Summary & Safe Capital Growth Plans - baoquankhu1.vn
Leerink Partners initiates Sutro Biopharma stock with outperform rating - Investing.com
Leerink Partners initiates Sutro Biopharma stock with outperform rating By Investing.com - Investing.com India
Leerink Partners initiates coverage of Sutro Biopharma (STRO) with outperform recommendation - MSN
Institution Moves: What is the Moat Score of Sutro Biopharma IncWeekly Risk Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Sutro Biopharma Hits New 52-Week High at $26.54, Up 548.83% - Markets Mojo
[EFFECT] SUTRO BIOPHARMA, INC. SEC Filing - Stock Titan
Market Outlook: Can Sutro Biopharma Inc continue delivering strong returns2026 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sutro Biopharma enters sales agreement, may offer & sell shares of common stock of up to $100 millionSEC filing - marketscreener.com
Sutro Biopharma Enters Sales Agreement, May Offer & Sell Shares Of Common Stock Of Up To $100 MillionSEC Filing - TradingView
Sutro Biopharma (NASDAQ: STRO) files $100M ATM shelf with TD Cowen - Stock Titan
Gains Report: Why is Sutro Biopharma Inc stock going down2026 Spike Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Earnings Risk: Is now the right time to enter Sutro Biopharma IncWeekly Stock Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Value Recap: Is Sutro Biopharma Inc in a bullish channelMarket Sentiment Summary & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Sutro Biopharma (STRO) price target increased by 13.85% to 37.74 - MSN
Hedge Fund Bets: What is the Moat Score of Sutro Biopharma Inc2026 Earnings Surprises & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Stock Market Recap: Is Sutro Biopharma Inc a potential multi baggerSell Signal & Reliable Intraday Trade Alerts - baoquankhu1.vn
HC Wainwright Lowers Earnings Estimates for Sutro Biopharma - marketbeat.com
Sutro Biopharma (NASDAQ:STRO) Upgraded by Truist Financial to "Strong-Buy" Rating - MarketBeat
Sutro Biopharma Faces Rising Operational Risks Amid Escalating U.S.-China Trade Tensions - The Globe and Mail
Sutro Biopharma Inc buy Deutsche Bank Aktiengesellschaft - sharewise.com
Analyst James Shin Raises Price Target for Sutro Biopharma (STRO) to $55.00 | STRO Stock News - GuruFocus
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Sutro Biopharma (NASDAQ:STRO) Stock Price - MarketBeat
Deutsche Bank Adjusts Sutro Biopharma Price Target to $55 From $51, Maintains Buy Rating - MarketScreener
HC Wainwright Predicts Sutro Biopharma FY2030 Earnings - MarketBeat
This Ralph Lauren Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Wells Fargo Upgrades Sutro Biopharma (STRO) with Significant Pri - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Raised to "Overweight" at Wells Fargo & Company - MarketBeat
Sutro Biopharma (NASDAQ:STRO) Raised to Buy at HC Wainwright - MarketBeat
Wells Fargo Upgrades Sutro Biopharma to Overweight From Equal Weight, Adjusts PT to $27 From $8 - MarketScreener
H.C. Wainwright upgrades Sutro Biopharma stock rating to buy By Investing.com - Investing.com Canada
H.C. Wainwright upgrades Sutro Biopharma stock rating to buy - Investing.com
Sutro's FY25 Net Loss Narrows; On Track To Report Initial Phase 1 Data Of STRO-004 In Mid-2026 - RTTNews
Citizens reiterates Sutro Biopharma stock rating on pipeline progress By Investing.com - ca.investing.com
STRO Stock: HC Wainwright & Co. Upgrades Sutro Biopharma | STRO - GuruFocus
Sutro Biopharma (STRO) Receives Upgrade with Promising Outlook - GuruFocus
Citizens reiterates Sutro Biopharma stock rating on pipeline progress - Investing.com
Sutro Biopharma Reports 2025 Financial Results, Advances Dual-Payload ADC Pipeline, and Extends Cash Runway to 2028 - Minichart
Sutro Biopharma Annual Report 2023: Business Overview, Risk Factors, and Financial Analysis - Minichart
Sutro Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sutro Biopharma (NASDAQ: STRO) launches $100M ATM program with TD Cowen - Stock Titan
Sutro Biopharma Ends ATM Agreement After 2025 Results - TipRanks
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights - Bitget
Sutro Biopharma Inc (STRO) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):